Guggenheim analyst Yatin Suneja reiterated a Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ: LRMR).The analyst commented: "Recently ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE